Iron deficiency in the practice of a gynecologist: therapeutic efficacy

In: Obstetrics, Gynecology and Reproduction · 2023 · vol. 17(2) , pp. 202–209 · doi:10.17749/2313-7347/ob.gyn.rep.2023.402 · W4377288183
article OA: gold CC0

Abstract

Introduction. Iron deficiency (ID) of varying severity is the most common and rather serious extra-gynecological complication of adenomyosis resulting from meno/metrorrhagia of varying intensity, up to abnormal uterine bleeding requiring surgical hemostasis. Taking into account the chronic course of the disease, the complexity of radical therapy as well as a systemic effect ID also particularly affecting reproductive system, an issue of sufficient and timely ID correction in patients with adenomyosis of varying severity remains relevant. Aim: to study an efficacy of ID therapy with drug containing ferrous fumarate and folic acid in patients with adenomyosis. Materials and Methods . An observational study was conducted, which included 90 patients with isolated adenomyosis of varying severity: 30 patients with degree 1 adenomyosis (group 1), 30 patients with degree 2 adenomyosis (group 2), 30 women with degree 3–4 (group 3). All patients received ferrous fumarate plus folic acid for 30 days. To identify an ID variant, the level of serum ferritin, iron, transferrin, total iron-binding capacity of blood serum (TIBC), clinical blood test parameters such as hemoglobin level, erythrocyte count, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC) were measured. Results. A significant increase in ferrokinetic parameters was found in all patient groups. The most significant and clinically important dynamics was noted for serum iron level and TIBC. For instance, after the therapy, the level of serum iron increased in group 1 from 11.0 ± 0.6 μmol/l up to 15.0 ± 1.1 μmol/l, in group 2 – from 9.0 ± 1.6 μmol/l up to 14 .0 ± 0.8 μmol/l, in group 3 from 7.0 ± 1.3 μmol/l up to 12.0 ± 1.3 μmol/l (p < 0.05). In addition, a decreased TIBC was found in group 3: from 68.0 ± 1.8 μmol/l down to 58.0 ± 1.7 μmol/l (p < 0.05); in groups 2 and 3 TIBC level tended to insignificantly decrease. Conclusion . The use of a preparation containing ferrous fumarate along with folic acid can effectively correct background ID of varying severity in patients with adenomyosis of varying intensity. An earlier and longer administration of iron preparations in patients with adenomyosis along with clinical and laboratory parameter monitoring is recommended to achieve more pronounced clinical effect.
Full text 5,900 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

Introduction. Iron deficiency (ID) of varying severity is the most common and rather serious extra-gynecological complication of adenomyosis resulting from meno/metrorrhagia of varying intensity, up to abnormal uterine bleeding requiring surgical hemostasis. Taking into account the chronic course of the disease, the complexity of radical therapy as well as a systemic effect ID also particularly affecting reproductive system, an issue of sufficient and timely ID correction in patients with adenomyosis of varying severity remains relevant. Aim: to study an efficacy of ID therapy with drug containing ferrous fumarate and folic acid in patients with adenomyosis.

Materials

and Methods. An observational study was conducted, which included 90 patients with isolated adenomyosis of varying severity: 30 patients with degree 1 adenomyosis (group 1), 30 patients with degree 2 adenomyosis (group 2), 30 women with degree 3–4 (group 3). All patients received ferrous fumarate plus folic acid for 30 days. To identify an ID variant, the level of serum ferritin, iron, transferrin, total iron-binding capacity of blood serum (TIBC), clinical blood test parameters such as hemoglobin level, erythrocyte count, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC) were measured. Results. A significant increase in ferrokinetic parameters was found in all patient groups. The most significant and clinically important dynamics was noted for serum iron level and TIBC. For instance, after the therapy, the level of serum iron increased in group 1 from 11.0 ± 0.6 μmol/l up to 15.0 ± 1.1 μmol/l, in group 2 – from 9.0 ± 1.6 μmol/l up to 14 .0 ± 0.8 μmol/l, in group 3 from 7.0 ± 1.3 μmol/l up to 12.0 ± 1.3 μmol/l (p < 0.05). In addition, a decreased TIBC was found in group 3: from 68.0 ± 1.8 μmol/l down to 58.0 ± 1.7 μmol/l (p < 0.05); in groups 2 and 3 TIBC level tended to insignificantly decrease. Conclusion. The use of a preparation containing ferrous fumarate along with folic acid can effectively correct background ID of varying severity in patients with adenomyosis of varying intensity. An earlier and longer administration of iron preparations in patients with adenomyosis along with clinical and laboratory parameter monitoring is recommended to achieve more pronounced clinical effect. About the Authors E. M. DzhobavaRussian Federation Eliso M. Dzhobava – MD, Dr Sci Med, Professor, Medical Director 10 bldg. 1, Tovarishcheskiy Lane, Moscow 109004 I. G. Knysheva Russian Federation Inessa G. Knysheva – MD, PhD, Gynecologist-Endocrinologist, General Director 10 bldg. 1, Tovarishcheskiy Lane, Moscow 109004 D. P. Artizanova Russian Federation Daria P. Artizanova – MD, Obstetrician-Gynecologist 10 bldg. 1, Tovarishcheskiy Lane, Moscow 109004

References

1. Konovodova E.N., Dokueva R.S-E., Yakunina N.A. Iron deficiency in obstetric and gynecological practice. [Zhelezodeficitnye sostoyaniya v akushersko-ginekologicheskoj praktike]. RMZh. Mat' i ditya. 2011;19(20):1228–31. (In Russ.). 2. Pasricha S.-R.S., Flecknoe-Brown S.C., Allen K.J. et al. Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust. 2010;193(9):525–32. https://doi.org/10.5694/j.1326-5377.2010.tb04038.x. 3. Serov V.N., Dubrovina N.V., Balushkina A.A. Iron deficiency anemia in gynecological practice: basic principles of treatment. [Zhelezodeficitnaya anemiya v ginekologicheskoj praktike: osnovnye principy lecheniya]. RMZh. Mat' i ditya. 2011;19(1):1–4. (In Russ.). 4. Gorodetsky V.V., Godulyan O.V. Iron deficiency states and iron deficiency anemia: diagnosis and treatment. Guidelines. [Zhelezodeficitnye sostoyaniya i zhelezodeficitnaya anemiya: diagnostika i lechenie. Metodicheskie rekomendacii]. Moscow: Medpraktika-M, 2005. V. 3. 28 p. (In Russ.). 5. Kozlovskaya L.V. Hypochromic anemia: differential diagnosis and treatment. [Gipohromnye anemii: differencial'nyj diagnoz i lechenie]. Novyj medicinskij zhurnal. 1996;56:8–12. (In Russ.). 6. UNICEF/UNU/WHO. Iron Deficiency Anemia: Assessment, Prevention, and Control. A Guide for Programme Managers. Geneva: WHO/NHD, 2001. 132 p. Available at: http://s2.medicina.uady.mx/observatorio/docs/an/li/AN2001_Li_WHO.pdf. [Accessed: 10.02.2023]. 7. Lebedev V.A., Pashkov V.M. Treatment of iron deficiency anemia in patients with gynecological disorders. [Principy terapii zhelezodeficitnoj anemii u ginekologicheskih bol'nyh]. Trudnyj pacient. 2013;(1):3–7. (In Russ.). 8. Dvoretsky L.I., Zaspa E.A. Iron deficiency anemia in the practice of obstetrician-gynecologist. [Zhelezodeficitnye anemii v praktike akushera-ginekologa]. RMZh. 2008;16(29):1898–905. (In Russ.). 9. Clinical guidelines. Endometriosis. Moscow: Health Ministry of Russian Federation, 2020. 60 p. Available at: https://minzdrav.samregion.ru/wp-content/uploads/sites/28/2020/12/endometrioz.pdf. [Accessed: 10.02.2023]. 10. Fernаndez-Gaxiola A.C., De-Regil L.M. Intermittent iron supplementation for reducing anaemia and its associated impairments in menstruating women. Cochrane Database Syst Rev. 2019;1(1):CD009218. https://doi.org/10.1002/14651858.CD009218.pub3. 11. Vertkin A.L., Godulyan O.V., Gorodetsky V.V., Skotnikov A.S. Iron deficiency anemia and drug choice for its correction. [Zhelezodeficitnaya anemiya i vybor preparata dlya ee korrekcii]. RMZh. Medicinskoe obozrenie. 2010;(5):260. (In Russ.). Review For citations: Dzhobava E.M., Knysheva I.G., Artizanova D.P. Iron deficiency in the practice of a gynecologist: therapeutic efficacy. Obstetrics, Gynecology and Reproduction. 2023;17(2):202-209. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.402 JATS XML This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (2)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK